12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TH-302: Interim Phase I/II data

Data from 12 evaluable patients in the first part of a 3-part, open-label, U.S. Phase I/II trial showed that TH-302 plus dexamethasone led to 2 partial responses, 2 minimal responses and 8 cases of stable disease. Patients received 240, 340 or 480 mg/m 2 plus 40 mg dexamethasone on days 1, 4, 8 and 11 of a 21-day cycle. There were 2 DLTs of grade 3 stomatitis at...

Read the full 318 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >